
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio Inc is positioning itself favorably in the biopharmaceutical sector by significantly increasing its R&D expenditures, which rose 23% to $21.0 million, indicating a strong commitment to advancing its innovative RNA editing technologies. The reduction in operating expenses by 13% to $20.3 million highlights the company’s strategic efforts to manage costs while still driving their research initiatives, thereby enhancing cash runway into 2H27. Additionally, the recognition of $1.1 million in collaborative revenue from a partnership with Novo Nordisk underlines the potential for further growth and financial stability as the company continues to explore new therapeutic opportunities.
Bears say
Korro Bio Inc faces significant challenges that contribute to a negative outlook on its stock. The potential for inferior pharmacologic profiles compared to existing therapies poses a risk to the company’s marketing and return on investment capabilities, particularly if clinical trials do not meet expectations. Additionally, there are concerns regarding the necessity for capital raises, which could dilute shares and adversely affect the company's ability to execute its development plans, compounded by the inherent volatility of the biotech sector.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares